FHTX - Company ID 0001822462
The table below shows Foghorn Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M | $430.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $85.47M | $94.53M | $109.69M | $105.62M | $80.33M | $57.72M |
| SG&A |
Foghorn Therapeutics Inc. reported annual revenue of $30.91M for fiscal year 2025. That is up 36.8% from $22.60M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $430.00K (FY 2020) to $30.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $27.55M |
| $28.36M |
| $32.37M |
| $30.75M |
| $21.73M |
| $11.25M |
| Operating income | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M | -$68.53M |
| Income tax | $0.00 | $0.00 | $4.23M | $0.00 | - | $0.00 |
| Net income | -$74.28M | -$86.62M | -$98.43M | -$108.88M | -$101.32M | -$68.80M |
| EPS (diluted) | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 |